EC Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

EC Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 34.6% bzw. 14.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 34.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.2% betragen.

Wichtige Informationen

34.6%

Wachstumsrate der Gewinne

34.3%

EPS-Wachstumsrate

Consumer Services Gewinnwachstum	16.9%
Wachstumsrate der Einnahmen	14.1%
Zukünftige Eigenkapitalrendite	10.2%
Analystenabdeckung	Low
Zuletzt aktualisiert	01 Mar 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

Dec 24

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

Dec 08

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

Dec 01

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Sep 15

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Aug 24

Is EC Healthcare (HKG:2138) Using Too Much Debt?

Aug 10

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Jul 14

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Jun 26

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

Jun 15

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

May 12

Is EC Healthcare (HKG:2138) Potentially Undervalued?

Mar 08

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Feb 03

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Dec 20

Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?

Oct 25

EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return

Sep 20

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

Sep 01

EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 28

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

Jul 14

EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042

Jun 26

When Should You Buy EC Healthcare (HKG:2138)?

May 26

EC Healthcare (HKG:2138) Will Be Hoping To Turn Its Returns On Capital Around

Apr 18

Is It Too Late To Consider Buying EC Healthcare (HKG:2138)?

Feb 24

EC Healthcare (HKG:2138) Could Easily Take On More Debt

Feb 11

EC Healthcare (HKG:2138) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Dec 26

EC Healthcare Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Dec 02

EC Healthcare (HKG:2138) May Have Issues Allocating Its Capital

Nov 25

Should You Investigate EC Healthcare (HKG:2138) At HK$11.10?

Nov 03

EC Healthcare (HKG:2138) Is Paying Out A Larger Dividend Than Last Year

Aug 24

Gewinn- und Umsatzwachstumsprognosen

SEHK:2138 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (HKD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2026	5,751	301	690	1,453	4
3/31/2025	5,043	201	421	1,095	5
3/31/2024	4,279	47	338	578	4
9/30/2023	4,104	-4	317	729	N/A
6/30/2023	3,989	33	255	667	N/A
3/31/2023	3,875	70	193	605	N/A
12/31/2022	3,622	93	162	499	N/A
9/30/2022	3,369	117	132	392	N/A
6/30/2022	3,144	157	240	500	N/A
3/31/2022	2,920	198	348	608	N/A
12/31/2021	2,823	253	479	684	N/A
9/30/2021	2,727	309	610	760	N/A
6/30/2021	2,404	251	541	690	N/A
3/31/2021	2,080	193	472	621	N/A
12/31/2020	1,854	163	487	597	N/A
9/30/2020	1,627	133	503	573	N/A
6/30/2020	1,788	210	505	574	N/A
3/31/2020	1,949	287	507	576	N/A
12/31/2019	2,023	325	273	452	N/A
9/30/2019	2,098	364	40	327	N/A
6/30/2019	1,975	363	-5	283	N/A
3/31/2019	1,852	361	-49	238	N/A
12/31/2018	1,715	355	108	278	N/A
9/30/2018	1,578	348	265	317	N/A
6/30/2018	1,450	314	269	320	N/A
3/31/2018	1,322	279	272	324	N/A
12/31/2017	1,253	266	251	302	N/A
9/30/2017	1,183	253	230	280	N/A
6/30/2017	1,079	227	N/A	230	N/A
3/31/2017	975	201	N/A	180	N/A
12/31/2016	878	170	N/A	123	N/A
9/30/2016	780	139	N/A	66	N/A
6/30/2016	744	144	N/A	71	N/A
3/31/2016	708	149	N/A	76	N/A
12/31/2015	688	166	N/A	105	N/A
9/30/2015	668	183	N/A	134	N/A
6/30/2015	645	179	N/A	146	N/A
3/31/2015	621	174	N/A	159	N/A
3/31/2014	490	81	N/A	145	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 2138 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.2%).

Ertrag vs. Markt: 2138 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: 2138 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: 2138Die Einnahmen des Unternehmens (14.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.9% pro Jahr).

Hohe Wachstumseinnahmen: 2138Die Einnahmen des Unternehmens (14.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 2138Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.2%).

EC Healthcare Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 15% to HK$5.22

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

Consensus EPS estimates fall by 31%

Price target decreased by 11% to HK$8.03

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Price target increased to HK$9.33

Recent updates

EC Healthcare to Report Fiscal Year 2024 Results on Jun 27, 2024

An undisclosed buyer entered into an agreement to acquire additional 51% stake in Preeminent Medical Centre Limited from EC Healthcare (SEHK:2138) for HKD 80.2 million.

EC Healthcare (HKG:2138) Surges 25% Yet Its Low P/S Is No Reason For Excitement

When Should You Buy EC Healthcare (HKG:2138)?

Is EC Healthcare (HKG:2138) A Risky Investment?

New minor risk - Share price stability

EC Healthcare (SEHK:2138) entered into sale and purchase agreement to acquire 6.49% stake in Pangenia Inc from Sharp Point Consultant Limited for HKD 17.4 million.

Slammed 26% EC Healthcare (HKG:2138) Screens Well Here But There Might Be A Catch

EC Healthcare's (HKG:2138) Dividend Is Being Reduced To HK$0.005

EC Healthcare Announces the Resignation of Mr. Wong Chi Cheung as Executive Director and Chief Digital Officer of the Company with Effect from 31 December 2023

Price target decreased by 15% to HK$5.22

First half 2024 earnings released: EPS: HK$0.006 (vs HK$0.068 in 1H 2023)

Here's What's Concerning About EC Healthcare's (HKG:2138) Returns On Capital

EC Healthcare Declares an Interim Dividend for the Six Months Ended 30 September 2023, Payable on January 19, 2024

Ec Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2023

EC Healthcare to Report First Half, 2024 Results on Nov 30, 2023

EC Healthcare Announces Executive Changes

At HK$3.13, Is EC Healthcare (HKG:2138) Worth Looking At Closely?

Ec Healthcare Approves Dividend for the Year Ended 31 March 2023, Payment Date Is 18 September 2023

Upcoming dividend of HK$0.042 per share at 2.6% yield

EC Healthcare (HKG:2138) Is Paying Out A Dividend Of HK$0.042

Ec Healthcare Approves Final Dividend for the Year Ended 31 March 2023

Is EC Healthcare (HKG:2138) Using Too Much Debt?

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare (HKG:2138) Has Announced A Dividend Of HK$0.042

Consensus EPS estimates fall by 31%

EC Healthcare (HKG:2138) Will Pay A Dividend Of HK$0.042

Price target decreased by 11% to HK$8.03

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare, Annual General Meeting, Aug 23, 2023

EC Healthcare Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2023

Is There Now An Opportunity In EC Healthcare (HKG:2138)?

EC Healthcare to Report Fiscal Year 2023 Final Results on Jun 23, 2023

Be Wary Of EC Healthcare (HKG:2138) And Its Returns On Capital

Is EC Healthcare (HKG:2138) Potentially Undervalued?

EC Healthcare (HKG:2138) Will Want To Turn Around Its Return Trends

Price target increased to HK$9.33

Price target increased to HK$8.04

Upcoming dividend of HK$0.058 per share

EC Healthcare (HKG:2138) Is Paying Out Less In Dividends Than Last Year

Investor sentiment improved over the past week

Consensus forecasts updated

First half 2023 earnings released

EC Healthcare Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 20 January 2023

Price target decreased to HK$8.89

Less than half of directors are independent

EC Healthcare Provides Earnings Guidance for the Six Months Ended 30 September 2022

EC Healthcare to Report Q2, 2023 Results on Nov 24, 2022

Investor sentiment improved over the past week

Is Now An Opportune Moment To Examine EC Healthcare (HKG:2138)?

Price target decreased to HK$10.17

Investor sentiment deteriorated over the past week

EC Healthcare (HKG:2138) Is Reinvesting At Lower Rates Of Return

Chairman & Co-CEO recently bought HK$587k worth of stock

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

EC Healthcare Announces Executive Changes

Upcoming dividend of HK$0.042 per share

EC Healthcare Approves Final Dividend for the Year Ended 31 March 2022, Payable on 20 September 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare's (HKG:2138) Shareholders Will Receive A Smaller Dividend Than Last Year

EC Healthcare Proposes Final Dividend for the Year Ended 31 March 2022

EC Healthcare's (HKG:2138) Dividend Will Be Reduced To HK$0.042

EC Healthcare (HKG:2138) Is Reducing Its Dividend To HK$0.042

EC Healthcare, Annual General Meeting, Aug 23, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EC Healthcare to Report Fiscal Year 2022 Final Results on Jun 23, 2022

When Should You Buy EC Healthcare (HKG:2138)?

EC Healthcare (SEHK:2138) entered into agreement to acquire 75% stake in Mobile Medical International Holdings Limited from certain existing shareholders for HKD 41.25 million.